I
mmunovia AB, ("Immunovia") a diagnostic company that develops highly accurate blood tests for the early detection of cancer and autoimmune diseases, today announced results from a study in their development pipeline, published in the peer-reviewed Journal of Proteome Research. These are the first proteomic data allowing a differential analysis of four different inflammatory rheumatic diseases (IRDs).
Early and correct diagnosis of inflammatory rheumatic diseases is presently a clinical challenge due to the variety of symptoms. The aim of the study was to achieve protein expression profiles distinguishing four systemic IRDs, that if left untreated, can lead to severe and sometimes permanent disability, increased morbidity, and premature mortality. A total of 316 serum samples collected from patients with Systemic Lupus Erythematosus (SLE), ANCA associated systemic vasculitis (SV), Rheumatoid Arthritis (RA) and Sjögren's Syndrome (SS), and healthy controls were analysed, using Immunovia's recombinant antibody microarray (IMMray™). Differential protein expression profiling was examined using Wilcoxon signed rank test and condensed biomarker panels could be identified reflecting each disease, using advanced bioinformatics and state-of-the art classification algorithms.